APLT Stock Financial Analysis - Applied Therapeutics, Inc. (NasdaqCM) Stock

Overview

Applied Therapeutics, Inc., based in the United States, is a biopharmaceutical company focused primarily on the development of novel treatments in the areas of metabolic and cardiorenal diseases. A significant endeavor for the company involves the advanced clinical development of its flagship drug candidate, AT-007, a central nervous system penetrant aldose reductase inhibitor, designed for the treatment of Galactosemia, a rare pediatric metabolic disease. Applied Therapeutic's innovative therapeutic approach also extends to addressing diabetic complications and other rare diseases through a pipeline fashioned to disrupt existing treatment paradigms. The company operates at the forefront of addressing unmet medical needs by advancing its proprietary technology and through rigorous clinical trials to prove efficacy and safety of its products.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for Applied Therapeutics, Inc. as of June 30, 2025 is 0.12 MM.
The operating income for Applied Therapeutics, Inc. as of June 30, 2025 is -111.39 MM.
The net income for Applied Therapeutics, Inc. as of June 30, 2025 is -67.74 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30	0.12	-111.39	-67.74
2025-03-31	0.27	-108.73	-43.51
2024-12-31	0.46	-104.30	-105.62
2024-09-30	-0.21	-92.28	-187.31
2024-06-30	-0.33	-78.03	-161.09
2024-03-31	-0.48	-74.77	-193.56
2023-12-31	9.99	-64.53	-119.76
2023-09-30	10.66	-62.50	-96.51
2023-06-30	10.66	-66.36	-73.24
2023-03-31	10.66	-70.71	-69.52
2022-12-31		-82.95	-82.51
2022-09-30		-91.09	-95.24
2022-06-30		-100.17	-104.56
2022-03-31		-104.52	-104.53
2021-12-31		-105.62	-105.58
2021-09-30		-102.25	-102.11
2021-06-30		-103.79	-103.54
2021-03-31		-106.20	-105.77
2020-12-31		-94.47	-93.96
2020-09-30		-88.39	-87.91

Income Statement: EPS

The earnings per share basic for Applied Therapeutics, Inc. as of June 30, 2025 is -0.47.
The earnings per share diluted for Applied Therapeutics, Inc. as of June 30, 2025 is -0.48.

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30	-0.47	-0.48
2025-03-31	-0.30	-0.30
2024-12-31	-0.76	-0.76
2024-09-30	-1.43	-1.43
2024-06-30	-1.37	-1.36
2024-03-31	-1.91	-1.91
2023-12-31	-1.42	-1.42
2023-09-30	-1.40	-1.40
2023-06-30	-1.25	-1.26
2023-03-31	-1.53	-1.53
2022-12-31	-2.18
2022-09-30	-2.99	-2.99
2022-06-30	-3.97	-3.97
2022-03-31	-4.00	-4.00
2021-12-31	-4.12
2021-09-30	-4.13	-4.14
2021-06-30	-4.35	-4.36
2021-03-31	-4.64	-4.64
2020-12-31	-4.28	-4.28
2020-09-30	-4.72	-4.72

Cash Flow: Operations, Investing, Financing

The cash from operating activities for Applied Therapeutics, Inc. as of June 30, 2025 is -91.78 MM.
The cash from financing activities for Applied Therapeutics, Inc. as of June 30, 2025 is 0.00 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	-91.78		0.00
2025-03-31	-94.03		-1.69
2024-12-31	-84.31		113.81
2024-09-30	-81.84	0.00	143.25
2024-06-30	-73.24	0.00	159.82
2024-03-31	-67.09	0.00	190.66
2023-12-31	-55.17	13.87	74.54
2023-09-30	-54.06	6.97	44.16
2023-06-30	-58.73	11.99	26.62
2023-03-31	-60.67	17.52	27.86
2022-12-31	-78.09	13.17	27.69
2022-09-30	-89.14	31.88	27.44
2022-06-30	-85.42	35.38	27.33
2022-03-31	-92.92	46.63	0.44
2021-12-31	-90.73	12.43	74.72
2021-09-30	-86.54	29.07	78.99
2021-06-30	-91.56	-9.69	78.84
2021-03-31	-81.57	-2.43	75.56
2020-12-31	-78.21	-19.47	136.29
2020-09-30	-67.87	-48.04	151.52

Valuation Metrics : PE, PriceToBook, PriceToTBV

The p/e for Applied Therapeutics, Inc. as of June 30, 2025 is -1.01.
The p/book for Applied Therapeutics, Inc. as of June 30, 2025 is 1.20.
The p/tbv for Applied Therapeutics, Inc. as of June 30, 2025 is 1.20.

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30	-1.01	1.20	1.20
2025-03-31		10.20	10.20
2024-12-31		16.09	16.09
2024-09-30	-5.90	13.12	13.12
2024-06-30	-2.74	7.88	7.88
2024-03-31	-6.06	-42.30	-42.30
2023-12-31	-2.68	-23.39	-23.39
2023-09-30	-2.15	-36.41	-36.41
2023-06-30	-1.09	-18.61	-18.61
2023-03-31	-0.47	9.58
2022-12-31		3.79	3.79
2022-09-30		1.73	1.73
2022-06-30	-0.40	1.01	1.01
2022-03-31	-0.52	0.88	0.88
2021-12-31	-2.29	2.69	2.69
2021-09-30	-4.21	3.88	3.88
2021-06-30
2021-03-31	-0.50	0.39	0.39
2020-12-31	-0.49	0.56	0.56
2020-09-30	-0.52	0.45	0.45

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

The ebit/ev for Applied Therapeutics, Inc. as of June 30, 2025 is 6.48.
The ebit (3y)/ev for Applied Therapeutics, Inc. as of June 30, 2025 is 13.79.

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30	6.48	13.79
2025-03-31	4.83	3.87
2024-12-31	46.40	32.17
2024-09-30	-0.19	-0.14
2024-06-30	-0.50	-0.32
2024-03-31	-0.18	-0.15
2023-12-31	-0.44	-0.44
2023-09-30	-0.59	-0.76
2023-06-30	-1.30	-1.73
2023-03-31	-3.61	-4.27
2022-12-31	41.24	41.18
2022-09-30	12.19	11.45
2022-06-30	-21.48	-18.96
2022-03-31	-47.65	-39.19
2021-12-31	-0.62	-0.49
2021-09-30	-0.29	-0.21
2021-06-30
2021-03-31	3.56	2.00
2020-12-31	9.14	5.06
2020-09-30	177.66	82.53

Management Effectiveness

The roa for Applied Therapeutics, Inc. as of June 30, 2025 is -0.34.
The roe for Applied Therapeutics, Inc. as of June 30, 2025 is -0.60.
The roic for Applied Therapeutics, Inc. as of June 30, 2025 is -1.11.
The croic for Applied Therapeutics, Inc. as of June 30, 2025 is -2.43.
The ocroic for Applied Therapeutics, Inc. as of June 30, 2025 is -2.39.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	-0.34	-0.60	-1.11	-2.43	-2.39
2025-03-31	-1.24	-2.78	-23.82	7.81	-10.41
2024-12-31	-3.42		-23.82	7.81	-10.41
2024-09-30	-3.56		-2.22	1.19	-1.01
2024-06-30	-6.45		-2.85	1.82	-0.99
2024-03-31	-3.12	-29.49
2023-12-31	-1.70	-10.02
2023-09-30	-0.94	-2.84
2023-06-30	-0.89	-2.69
2023-03-31	-1.27	-1.97
2022-12-31	-0.80	-1.10	-7.81	-2.45	-7.31
2022-09-30	-0.88	-1.21	-7.26	-2.27	-6.79
2022-06-30	-0.76	-0.93	-3.77	-0.82	-3.08
2022-03-31	-0.68	-0.78	-2.38	-1.04	-2.11
2021-12-31	-0.98	-1.25	-1.60	-0.05	-0.96
2021-09-30	-0.82	-1.01	-1.12	0.24	-0.78
2021-06-30	-0.69	-0.80	-0.88	-0.19	-0.78
2021-03-31	-0.64	-0.68	-0.77	-0.06	-0.59
2020-12-31	-1.94	-2.88	-1.11	0.46	-0.92
2020-09-30	-2.36	-2.86	-0.82	0.33	-0.64

Gross Margins

The gross margin for Applied Therapeutics, Inc. as of June 30, 2025 is -166.41.
The net margin for Applied Therapeutics, Inc. as of June 30, 2025 is -164.19.
The operating margin for Applied Therapeutics, Inc. as of June 30, 2025 is -410.31.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30	-166.41	-164.19	-410.31
2025-03-31	430.03	883.54	435.31
2024-12-31	430.03	883.54	435.31
2024-09-30	146.07	483.75	234.34
2024-06-30	105.94	405.79	156.75
2024-03-31	-4.39	-11.98	-6.46
2023-12-31	1.00	-9.05	-5.86
2023-09-30	1.00	-6.87	-6.23
2023-06-30	1.00	-6.87	-6.23
2023-03-31		-6.52	-6.63
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30